Related Experiment Video

Updated: Jul 18, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Plasma beta-thromboglobulin in patients with valvular heart disease with or without valve replacement: relationship

J Conard, M H Horellou, M Baillet

    European Heart Journal
    |October 1, 1984
    PubMed

    Insights

    Plasma beta-thromboglobulin (BTG) levels are elevated in valvular heart disease patients, particularly those with a history of thromboembolism. Further research is needed to confirm BTG

    Area of Science:

    • Cardiology
    • Hematology
    • Biochemistry

    Background:

    • Valvular heart disease (VHD) can lead to platelet count and retention abnormalities.
    • Plasma beta-thromboglobulin (BTG) is a marker of platelet activation.

    Purpose of the Study:

    • To investigate plasma BTG levels in patients with VHD before and after valve replacement surgery.
    • To assess the relationship between BTG levels, prosthetic valve type, and history of thromboembolism.

    Main Methods:

    • Plasma BTG levels were measured in 132 VHD patients.
    • Patients were categorized based on pre- or post-surgery status, prosthetic valve type (mechanical vs. bioprosthesis), and history of thromboembolism.
    • BTG levels were compared to a control group.

    Main Results:

    • VHD patients exhibited increased BTG levels compared to controls.
    • No significant difference in BTG levels was found between patients with mechanical valves versus no prosthesis.
    • BTG levels were significantly higher in patients with a history of thromboembolism.

    Conclusions:

    • Plasma BTG may serve as a valuable indicator in VHD management.
    • BTG evaluation warrants further investigation in prospective studies for VHD patients.
    • Elevated BTG in VHD patients with thromboembolism history suggests a role in thrombotic events.

    More Related Videos

    Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization06:28

    Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

    Published on: June 4, 2020

    In Vitro Thrombosis Test for Ventricular Assist Devices09:15

    In Vitro Thrombosis Test for Ventricular Assist Devices

    Published on: March 21, 2025

    Related Concept Videos

    Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

    Anticoagulant Drugs: Low-Molecular-Weight Heparins

    Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
    Venous Thrombosis I: Introduction01:30

    Venous Thrombosis I: Introduction

    Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

    The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Pulmonary Embolism I: Introduction01:29

    Pulmonary Embolism I: Introduction

    Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
    Pulmonary Embolism I: Introduction01:19

    Pulmonary Embolism I: Introduction

    A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...